Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus FLUOTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus FLUOTREX.
ARAZLO vs FLUOTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
The active metabolite of FLUOTREX, 5-fluorouracil (5-FU), inhibits thymidylate synthase, leading to depletion of thymidine triphosphate and inhibition of DNA synthesis. Additionally, it incorporates into RNA, disrupting RNA function.
Topical: Apply 0.045% gel once daily to affected areas of the face.
20 mg/m2 intramuscularly once weekly, not to exceed 30 mg/m2 per week.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function. In patients with renal impairment, half-life may be prolonged up to 10-15 hours, necessitating dose adjustment.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily renal excretion as unchanged drug (approximately 60-70% of administered dose), with the remainder eliminated via biliary/fecal routes (20-30%) and minor metabolic clearance.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid